Metabolic syndrome (MS) is a condition, which constitutes a group of risk factors that occur together and increase the risk for Coronary Artery Disease, Stroke and type 2 diabetes mellitus. This disorder is found prevalent in the industrialized societies of the world in epidemic proportions. Periodontitis is an oral disease of microbial origin characterized by loss of attachment apparatus of tooth, resulting in edentulism if untreated. Periodontitis has been attributed to produce a low grade systemic infl ammatory condition. The link of periodontitis to various systemic disorders has led to the evolution of a new branch termed as "periodontal medicine." Studies reviewed in the present paper have indicated a positive link between the MS and periodontitis and it is suggested that subjects displaying several components of MS should be submitted to periodontal examination. Present studies have displayed coherent relation between the two entities. This review will address the vicious association between MS and periodontitis, depicting the commonality of pathophysiological pathway between the two entities. Systematic reviews, meta-analysis addressing the concerned subject were screened. Whether the systematic periodontal therapy in individuals exhibiting MS has the potential to reduce the incidence of various adverse systemic complications remains a logical proposition. Further, longitudinal and controlled trials with a large population would be imperative to depict the robustness in the association between MS and periodontal disease in human subjects.
INTRODUCTION
The developing countries serve as a major contributor to the global increase in cardiovascular disease (CVD) through the increased mortality and prevalence of metabolic syndrome (MS). MS is a widely prevalent and multi-factorial disorder, also known by other names such as Reaven's syndrome, insulin resistance (IR) syndrome, plurimetabolic syndrome, syndrome X and the deadly quartet. MS is a confi guration of multiple system abnormalities characterized by hyperglycemia, central obesity, abnormal cholesterol and triglyceride (TG) levels and hypertension (HT). [1] MS has attracted immense clinical signifi cance since the last two decades. Prevailing data suggests that obesity and MS are immediate precursors of type 2 diabetes mellitus (T2DM) and CVD. [2] Various defi nitions of MS have been proposed over the years, punctuating on IR or abdominal/visceral obesity. International Diabetes Federation proposed a new defi nition based on clinical criteria [ Tables 1 and 2] . [3] Periodontitis is a common, chronic, low-grade infl ammatory disease of microbial origin, affecting humans and resulting in the destruction of tooth supporting apparatus. The signs and symptoms of periodontitis include swollen gums, deepening of the gingival crevice leading to the formation of periodontal pocket, bleeding on brushing, increased spacing between the teeth, loose teeth, teeth loss and edentulism can occur if the periodontal treatment is not instituted in these subjects. Recent studies have indicated that periodontitis may have an unfathomed effect on the systemic health. A vivid exploration of the cryptic mechanisms linking periodontitis to systemic disorders has ensued into the development of a new branch termed "periodontal medicine." [4] 
METHODS OF DATA COLLECTION
Studies examining the association of MS with periodontitis were identifi ed using PubMed search with key search terms such as "MS," "obesity," "type 2 diabetes," "dyslipidemia," "periodontitis" and "periodontal therapy (PT)." Systematic reviews, meta-analysis addressing the concerned subject were screened. Only human studies published in English language were considered. The text of the manuscript has been prepared by screening PUBMED database from January 1990 to March 2012.
ETIOPATHOGENESIS OF PERIODONTITIS
Dental plaque consists of at least 800 bacterial species. [5] Subgingival biofi lm houses the structured communities of microorganisms with noted heterogeneity, providing a signifi cant impetus for progression of periodontitis. During the past two decades with extensive research, we have come to realize that, although bacterial etiology is the prime component for the occurrence of periodontitis, its mere presence is inadequate for the disease to occur. Numerous host factors such as genetics, systemic health and environmental factors such as tobacco smoking, stress and various other risk factors may even preponderate the bacterial etiology for disease occurrence and prevail the severity of clinical disease expression. Thus, the recent conceptual model of periodontitis recognizes the various risk factors, which maneuver by modifying host responses, resulting in a change of disease expression. [6] In this model, host immune-infl ammatory mechanisms are triggered by bacteria and their products. Activation of the host response in turn induces the expression of antibodies and priming the polymorphonuclear neutrophils to counteract the microbial challenge in the gingival sulcus. Cytokines, prostanoids, matrix metalloproteinases expressed as a result to the host response, may actually augment the destruction of periodontal connective tissue. These observations have led to a greater scope in change of ideas and concepts about pathogenesis, prevention and treatment of periodontal diseases. The tissue destruction in periodontitis is characterized by the production of numerous cytokines that mediate infl ammatory mechanisms. Various cell types in the periodontium produce chemokines, including fi broblasts, endothelial cells, macrophages, osteoclasts, epithelial cells, neutrophils, monocytes, lymphocytes and mast cells. Neutrophils, monocytes and other cells produce innate immune cytokines such as interleukin (IL) and tumor necrosis factor-alpha (TNF-α) in the diseased periodontal site. These cytokines play an important role in bone resorption and periodontal tissue destruction. [7] Subgingival microbiota in periodontitis subjects serves as a signifi cant and persistent gram negative challenge to the host. These microbes and their toxic products such as Lipopolysaccharide (LPS) induce macrophages to secrete cytokines (IL-1α and 1β and TNF-α). [8] Elevated cell and cytokine-mediated markers of infl ammation, including C-reactive protein (CRP), [9] fi brinogen, [10, 11] matrix metalloproteinases [12] and various cytokines [13] are associated with periodontitis.
The periodontal bacteria and their noxious products gain ready access to the periodontal tissues and to the systemic circulation through the ulcerated sulcular epithelium of the gingiva in periodontitis. In untreated severe periodontitis, the accumulative surface area of ulcerated pocket epithelium liaison with the subgingival microbiota including their products, has been estimated to range from 15 cm 2 to 20 cm 2 , which is approximately the size of the palm of an adult hand. [8] Thus, severe chronic periodontitis exemplifi es a condition corresponding to subclinical septicemia. [14] Patients with periodontitis have been shown to demonstrate endotoxin activity in the serum. [15] Just as the periodontal tissues mount an immune-modulatory response to the bacteria and their products, systemic challenge with these agents also induces a major response. Some patients with periodontitis have reported to express tenfold increase in local and systemic expression of infl ammatory cytokines, such as TNF-α and IL-6, by monocytes and macrophages. [16] Since periodontitis itself ensues in the expression of pro-infl ammatory cytokines such as TNF-α and IL-6 it should be aptly considered as a systemic disorder. [17] The proinfl ammatory cytokines and periodontal bacteria enter the systemic circulation and produce a "low level systemic infl ammation/infection" [ Figure 1 ]. Thus, periodontitis has clinical implications reaching beyond the limits of the oral cavity and linking it to various systemic diseases. [13, 18] HYPERGLYCEMIA AND PERIODONTITIS T2DM is the most common metabolic disorder characterized by impaired glucose homeostasis. This condition is subsequent to a persistent deterioration of β cell function and hyperglycemia. IR is the salient feature of T2DM. The β cells fail to compensate for the IR, conducing to overt T2DM. [19] Increased oxidative stress and chronic subclinical systemic infl ammation is contributory to impaired glycemic control and increased IR; thus, paving a way for T2DM. [20, 21] Chronic hyperglycemia facilitates the nonenzymatic glycation of proteins with the formation of advanced glycation end products (AGEs). Although, AGEs are physiologically produced, in conditions of hyperglycemia this process is appreciably enhanced. AGEs are reported to prime the macrophages to express infl ammatory cytokines. These cytokines are instrumental in the release of acute phase reactants CRP from the liver, further exacerbating the existing infl ammation. [22] T2DM subjects with concomitant periodontitis exhibit increased biomarkers and oxidative stress. Impaired β cell function and enhanced IR is attributed to the intensifi ed oxidative stress as a result of hyperactivated neutrophils in periodontitis, resulting in the boosted release of reactive oxygen species. These subjects show decreased plasma antioxidant capacity. [23, 24] Periodontitis and T2DM reveal a commonality in the pathogenesis process, featuring infl ammatory response at the local and systemic level. [25] Various studies [26] [27] [28] [29] [30] have shown a bi-directional relationship between periodontal status and diabetes.
OBESITY AND PERIODONTITIS
Obesity is an excessive amount of body fat in proportion to lean body mass posing a risk to general health. Obesity is a chronic disease, with a multifactorial etiology. The most commonly used measure of body fat is the body mass index. [31] Obesity might represent a systemic condition, cognizable of regulating the onset and progression of periodontitis. The understanding with regards to adipose tissue has undergone a sea of change. Previously, adipose tissue was only considered as an inert organ, concerned with the storage of TGs. Currently, adipose tissue is reckoned as an endocrine organ, a major depot, capable of secreting bioactive agents called adipokines. [32] Some of the important adipokines are adiponectin (ADN), leptin, resistin, visfatin, chemerin, TNF-α, IL-1, IL-6, IL-8, IL-10, plasminogen activator inhibitor type-1 (PAI-1), monocyte chemoattractant protein-1 and retinol binding protein-4. Obesity ensues in decreased uptake Periodontitis is a risk factor for the establishment of atherosclerosis. [54] Studies have revealed that subjects with advanced chronic periodontitis show increased left ventricular mass. [54] [55] [56] [57] It is proposed that periodontitis induced systemic infl ammation may perpetuate atherosclerosis. A state of systemic infl ammation conduces to the stiffness of large arteries and increases the pulse wave velocity. This arterial stiffness as a result of impairment in elastic properties of large arteries could be a contributory mechanism to the pathogenesis of HT. Further, increased blood pressure adds to the risk of cardiovascular events. In hypertensive subjects, periodontitis may enhance the risk and degree of target organ damage. [57] [58] [59] [60] Although, the present literature shows a possible association between periodontitis and HT, the existence of a causal relationship needs to be ascertained. The effect of periodontitis on the blood pressure of periodontitis affected subjects and the increase of blood pressure with the deterioration in the degree of periodontitis should be examined. Welldesigned, prospective randomized controlled trials should be carried out henceforth.
ASSOCIATION OF PERIODONTITIS AND MS
MS as defi ned by Reaven consists of obesity, IR, HT, impaired glucose tolerance or diabetes, hyperinsulinemia and dyslipidemia characterized by elevated TG and low HDL concentrations. The constellation of the features mentioned above, are decipherable risk factors for atherosclerosis. [61] Fibrinolytic dysfunction, characterized by elevated levels of PAI-1 is implemental for the pathogenesis of cardiovascular events for subjects with MS. [62] Thus, MS is an established risk for coronary heart disease [63] and T2DM. [64] Various studies have demonstrated a statistically signifi cant association between established periodontitis and CVD. [16, 65] Recently, Buhlin et al. showed that periodontal infl ammation and bone loss is related to angiographically verifi ed coronary artery narrowing in patients with stable coronary artery disease or acute coronary syndrome. [66] Romagna et al., in across sectional study on 150 patients, demonstrated that bone loss in periodontitis is associated with a risk of multiple coronary lesions. [67] Studies have reported a positive association between MS and periodontitis [51, [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [ Table 3 ]. Two hypotheses could be suggested to explicate the relationship between periodontitis and MS. One hypothesis is a cause-effect relationship. However, longitudinal and of insulin by the liver, increased gluconeogenesis in the liver and dyslipidemia. There is a steep elevation in the TG level as a result of increase in free fatty acids. [33] The immunologic activity of these adipokines may play a signifi cant role in the development of IR and in periodontitis. Recent crosssectional studies and a meta-analysis have divulged positive associations between obesity and periodontal disease. [34] [35] [36] [37] [38] [39] [40] [41] Recently, Han et al. concluded that the visceral fat area was the most appropriate indicator of obesity in relation to periodontitis and that obesity could act as a substantial risk factor for periodontitis. [42] Although, the meta-analysis points to a positive association of obesity and periodontitis, the magnitude of the correlation is still not defi ned. This warrants further prospective studies to clarify the association.
DYSLIPIDEMIA AND PERIODONTITIS
Dyslipidemia is a state of abnormal lipid profi le, characterized by an increase in the serum concentrations of TGs, total cholesterol and low-density lipoprotein cholesterol, accompanied by a reduction in the levels of high-density lipoprotein (HDL) cholesterol. It has been proposed that this dyslipidemia conduits to a proinfl ammatory state, further leading to an increase in the levels of pro-infl ammatory cytokines and oxidative stress. The presence of systemic infl ammation can lead to the down regulation of host protective mechanisms. [43] The association between altered lipid profi le and periodontitis has been investigated in several studies. [44] [45] [46] [47] [48] [49] [50] [51] Although, it is suggested that dyslipidemia could be associated with periodontitis, its role as a risk factor is still under investigation. [52] Serum pro-infl ammatory cytokines may orchestrate a vital role in the association between periodontitis and dyslipidemia. It is proposed that periodontitis is not only associated with the severity of the deterioration of lipid metabolism, but also that the aggravation of hyperlipidemic state is linked with periodontal infl ammation by the up-regulation of serum and gingival crevicular fl uid pro-infl ammatory cytokines. [53] HT AND PERIODONTITIS HT is a highly prevalent chronic vascular disease, which is a signifi cant cause of cardiovascular morbidity and mortality. Current evidence implicates periodontitis as a risk factor for atherosclerotic cardiac disease and possibly peripheral arterial disease. [17] large-sample studies are needed to corroborate, which disease is the cause. The other hypothesis proposes a commonality in risk factors (excess caloric intake, sedentary life-style and poor oral hygiene) between the two conditions. [73] It is observed that periodontitis shares some common risk factors with MS, including hyperglycemia, obesity, dyslipidemia and elevated blood pressure. Although, the causative association of periodontitis with most of the mentioned factors is yet to be emphatically proven, periodontitis can pose as a risk factor, capable of modifying the disease course. The infl amed gingival tissue in periodontitis can act as a perennial source of pro-infl ammatory cytokines, bacteria and LPS furnishing the impulse for systemic infl ammation and infection [ Figure 1 ]. It has been reported that the association between periodontitis and MS could be bi-directional. [76] The infl ammatory markers in various components of MS can upregulate the periodontal infl ammatory process and the persistent periodontal infl ammation may worsen the infl ammatory components of MS [ Figure 2 ]. Obesity can result in exuberance of various cytokines, which can further exacerbate the periodontal infl ammation. It is demonstrated that subjects with MS have elevated levels of PAI-1, compared with healthy controls. [83] Tissue plasminogen activator and PAI-1 are instrumental in the pathogenesis of periodontitis by regulation of the proteolytic events in the extracellular matrix. [84] Obesity can affect the levels of PAI-1, which can promote periodontitis. Dyslipidemia and impaired glucose homeostasis can result in endothelial dysfunction. This may interrupt the blood supply to the periodontium. Nutritional defi ciency may play a role in the modulation of chronic disease [79] 7431 ≥20 years BMI, TG, HDL, HT, FPG, PD~ with ≥2 comp. MS ≈ perio; ↑obesity ≈ perio~ perio ≈ MS; obesity contributory in | K won et al. 2011 [80] process. [85] As a chronic infl ammatory disease process, periodontitis can also have an adverse effect on MS. Subjects with periodontitis display an increment in the levels of various infl ammatory markers in comparison to periodontal healthy controls. [86] Products of periodontal infl ammation may upgrade the levels of systemic cytokines, which may further enhance lipolysis. This may result in the increase of circulating TG [87] and exacerbate IR. [23] Nishimura et al. aptly proposed that periodontal disease should be considered as a component of MS. [25] Certain studies have revealed positive effects of nonsurgical PT on MS patients. PT has demonstrated amelioration in the tiers of infl ammatory markers, expressed by the components of MS. Shimada et al. investigated the results of PT on serum leptin and pro-infl ammatory cytokine levels in chronic periodontitis subjects. The study sample consisted of 33 chronic periodontitis and 18 patients with healthy periodontal status. Serum samples were evaluated for leptin, ADN, TNF-α, IL-6 and CRP levels before and after non-surgical PT. Non-surgical PT ensued in a signifi cant diminution of serum leptin, IL-6 and CRP levels. It was hence deduced that non-surgical PT is effi cacious in amending the dysmetabolic status. [88] Acharya et al. assessed the effect of PT in a sample of periodontitis patients with MS and other group of systemically healthy individuals (control group). The study design consisted of 31 subjects with chronic generalized periodontitis. This sample was segregated into16 subjects (Group A) diagnosed with MS and 15 subjects as healthy (Group B). Non-surgical PT was instituted in both groups. In both groups; high-sensitivity C-reactive protein (hs-CRP), total leukocyte count, parameters of lipid metabolism were evaluated at baseline and 2 months later. In the MS group, PT produced a signifi cant improvement in the levels of infl ammatory metabolic markers as compared with the baseline values. Systemically healthy group showed no statistical change in these markers. Thus, PT produced benefi cial effects in patients with MS and chronic periodontitis. [89] Sun et al. noted a signifi cant decrease in the serum levels of hs-CRP, TNF-α, IL-6, fasting plasma glucose, glycated hemoglobin, fasting insulin, IR index, TG in the T2DM group receiving PT as compared with the T2DM non treated group (P < 0.01 or P < 0.05). ADN levels also escalated signifi cantly in the treated group (P < 0.01). [90] Although this study did not involve MS subjects; it is notable to consider the positive infl uence of PT in the down regulation of various infl ammatory markers, associated with components of MS.
López et al. conducted a parallel-arm, double blind, randomized clinical study of 1 year duration in patients with MS and periodontitis. The experimental study group (n = 82) received scaling and root planning (SRP) plus antimicrobial therapy (amoxicillin and metronidazole) and the control group (n = 83) received only supra gingival scaling with placebo. Periodontal parameters and serum markers (lipid profi le, fi brinogen and hs-CRP levels) were evaluated at 3, 6, 9 and 12 months after therapy. A total of 79 patients in the study group and 81 patients in the control group fi nished the complete trial. Reduction in CRP levels was found to be statistically signifi cant at 9 (P = 0.024) and 12 months (P = 0.001) in both groups, without a difference between the groups. Fibrinogen levels diminished signifi cantly in the experimental group at 6 and 12 months, but not in the control group. Hence, it was inferred that elimination of periodontal infl ammation by SRP and antimicrobials had a salutary effect on the reduction of CRP levels in MS patients.
[91]
CONCLUSION
MS is likened to an epidemic gripping the modern civilization. Life-style, genetics, stress and dietary habits are the preliminary factors. Many studies point out to the positive relation of MS with periodontitis. Further longitudinal, long-term, well-designed, multi-centric studies based on a large sample sizes are mandatory to boost this relationship. With reference to the outcome of periodontal interventional studies in MS subjects there is still a vivid scope. The non-surgical PT is a relatively simple and cost-effective intervention consisting of SRP. SRP eliminates the microbial deposits favoring periodontal health. Gargantuan research in this area of periodontal medicine is anticipated. Periodontitis is a widely prevalent disease, but if diagnosed in the initial stage can be managed successfully without much morbidity. The outcome of therapy largely depends on the motivation and maintenance of patient. PT is noted to be instrumental in amelioration of the various infl ammatory biomarkers associated with MS. MS subjects should be recommended to go for frequent periodontal screening and PT should be instituted at the earliest if indicated. The respective governments should intensively focus on oral health-care programs for the treatment of periodontal diseases in developing countries. An orderly interdisciplinary approach by the physician and oral health-care professional is commended to control the severity of MS and restrict the morbidity and mortality attributed to the components of MS.
